Skip to content Skip to footer
Subscribe Now
Exclusive_Stacey Williams_2023
EXCLUSIVE

Stacey Williams, Vice President, Marketing, Dermavant Shares Insights on New Campaigns for Adults with Plaque Psoriasis

Shots:Stacey talked about the launch of its first streaming commercial as part of a direct-to-consumer advertising campaign for adults with plaque psoriasisThe “Topical Uprising” campaign focuses on the patient journey and taps into the frustrations & self-conscious of living with plaque psoriasis that helps patients to demand more from their topical plaque psoriasis treatmentThe…
January 23, 2023

Read more

Exclusive_Todd Zavodnick_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Todd Zavodnick of Dermavant Shares Insight on the Appointment of Nancy Beesley with 25+ Years of Experience

In an interview with PharmaShots, Todd Zavodnick, CEO at Dermavant, shared his views on the addition of Nancy Beesley to its Board of Directors. She brings over 25 years of experience in commercializing and branding therapeutics for the treatment of various dermatological, ophthalmic, and neurological conditions and rare diseasesShots:The addition of Nancy as a board member…
May 9, 2022

Read more

PharmaShots' Key Highlights of First Quarter 2022
INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2022

The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3BThe first quarter of the year also showcases regulatory events…
March 31, 2022

Read more

PharmaShots Interview Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof
VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

In an interview with PharmaShots, Philip Brown, Chief Medical Officer at Dermavant share his views on the data of Tapinarof in the P-III (PSOARING 3) study for the treatment of Plaque Psoriasis & highlights new patient satisfaction dataShots:The P-III (PSOARING 3) extension study evaluates tapinarof (1%, qd) in adult patients with PsO for ~40wks. & a 4wks. safety follow-up periodThe…
March 15, 2022

Read more

Viewpoints_Philip M. Brown
VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip M. Brown Shares Insights on the Clinical Data of Tapinarof Published in NEJM

In an interview with PharmaShots, Philip M. Brown, MD, JD, Chief Medical Officer at Dermavant shares his views on the P-III (PSOARING 1 & 2) trials of tapinarof for the treatment of Plaque PsoriasisShots:The P-III (PSOARING 1 & 2) trials evaluate the efficacy and safety of tapinarof (1%, qd) vs vehicle-controlled cream in a ratio (2:1) in 1025 patients aged…
February 8, 2022

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]